In wild-type (wt) RAS metastatic colorectal cancer (mCRC), the emergence of RAS mutant clones under the selective pressure of epidermal growth factor receptor (EGFR) inhibitors has been widely described, providing a molecular rationale for liquid biopsy-based adaptive therapies [4]. Here, EGFR is linked to metastatic colorectal cancer.